Home
Contact
✕
HER2+ breast cancer
Home
HER2+ breast cancer
Filter by
Categories
Tags
Authors
Show all
All
Editorials
New Trials
Ongoing Trials
Trial Results
All
Acute lymphoblastic leukemia
Adolescents and young adults
Advocacy
Anal cancer
Antioxidants
Bladder cancer
Blood cancers
Breast cancer
Cancer care delivery
Caregiving
Chemotherapy
Chronic lymphocytic leukemia
Communication
COVID-19
De-escalation
Esophagus cancer
GI cancer
Green tea
Head and neck cancer
Health equity
HER2+ breast cancer
Hormone therapy
Immune system therapy
Immunotherapy
In memory
Kidney cancer
Language
Late Effects
Leukemia
Liver cancer
Lung cancer
Lymphoma
Mammography
Mantle cell lymphoma
Melanoma
Mesothelioma
Minimal residual disease
MRI
Multiple myeloma
Myeloma
NCI-MATCH
Neuropathy
Nose and sinus cancer
Older adults
Pancreatic cancer
Pancreatic cysts
Patient-reported outcomes
Personalized medicine
Personalized screening
Personalized treatment
Precision medicine
Prevention
Prostate cancer
Renal cell carcinoma
Screening
Side effects
Squamous cell carcinoma
Surveillance
Survivorship
Symptom management
Targeted therapy
Throat cancer
Triple-negative breast cancer
Tumor test
All
Diane Dragaud
ecogacrinnews2
Katie Heller
June 7, 2020
June 7, 2020
Categories
New Trials
Now Enrolling: The CompassHER2 pCR trial is determining if certain patients with early-stage HER2 positive breast cancer may benefit from reduced chemotherapy
The purpose of this study is to find out if some patients with early-stage HER2 positive breast cancer can safely be treated with less chemotherapy than is generally used.
